Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 18:31:57 GMT 2025
by
admin
on
Tue Apr 01 18:31:57 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
RES3V2K0VC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
RES3V2K0VC
Created by
admin on Tue Apr 01 18:31:57 GMT 2025 , Edited by admin on Tue Apr 01 18:31:57 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_113 | 1_190 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_4 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
AGONIST
Ki
|
||
|
INHIBITOR -> TARGET |
Tepotinib also inhibited melatonin 2 and
imidazoline 1 receptors at clinically achievable concentrations.
|
||
|
|
AGONIST -> TARGET |
Ki
|
||
|
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
|
INHIBITOR->OFF-TARGET |
Ki
|
||
|
AGONIST -> TARGET |
AGONIST
Ki
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|